Abdavomeran

DB15695InvestigationalVaccines

BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech. BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the... BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived from T4 fibritin to increase immunogenicity.

Mechanism: Pharmacologically active on Spike glycoprotein
Curator reviewed
Also known as: BNT162b1 SARS-CoV-2 Vaccine
Code names: BNT162b1

Resolves to

Compound

UNIIJV8KBX6XZG

Targets

P0DTC2S

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Abdavomeran, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account